BioSpace News Archive

Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, provided an update on its clinical program for Namodenoson in the treatment of hepatocellular carcinoma, the most common form of liver cancer.

Amedisys, Inc., a leading provider of home health, hospice, personal care and high-acuity care, announced that Paul B. Kusserow, Chairman and Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9 at 8:15 p.m. ET.

Minerva Neurosciences, Inc. announced that, following the Type A meeting held on November 30, 2022, the Food and Drug Administration has confirmed that the refuse to file letter dated October 14, 2022 remains in effect in respect of the Company’s New Drug Application for roluperidone for the treatment of negative symptoms in patients with schizophrenia.

HTG Molecular Diagnostics, Inc., a life science company advancing precision medicine through its innovative transcriptome-wide profiling and advanced medicinal chemistry technology, provides here a summary of its second HTG Therapeutics key opinion leader webinar: “The Role of RNA Profiling in Drug Discovery and Analysis,” hosted on Tuesday, December 13, 2022.

Oncotelic Therapeutics, Inc, a clinical stage cancer and aging biotechnology company, issued a letter to its shareholders from its Chief Executive Officer, Dr. Vuong Trieu.

Polarean Imaging plc, the medical imaging technology company, announces that the U.S. Food and Drug Administration has granted approval for its drug device combination product, XENOVIEW.

Guardant Health, Inc., a leading precision oncology company, announced the company will be participating in the upcoming 41st Annual J.P. Morgan Healthcare Conference.

Cardio Diagnostics Holdings Inc, a leading precision cardiovascular diagnostics company, and Houston Concierge Medicine, a leading medical practice serving executives and health-forward consumers in Houston, announced the use of Cardio Diagnostics’ Epi+Gen CHD test.

Alzamend Neuro, Inc. announced that it is partnering with the Miller School of Medicine, Interdisciplinary Stem Cell Institute at the University of Miami for its Phase I/IIA clinical trial of ALZN002, a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer’s.

Varex Imaging Corporation announced that it is scheduled to present at CJS Securities 23rd Annual New Ideas for the New Year virtual investor conferences.